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Abstract
Introduction: Studies investigating genetic risk factors for susceptibility to rheumatoid arthritis (RA) studied anti-
citrullinated peptide antibody (CCP)-positive RA more frequently than anti-CCP-negative RA. One of the reasons for
this is the perception that anti-CCP-negative RA may include patients that fulfilled criteria for RA but belong to a
wide range of diagnoses. We aimed to evaluate the validity of this notion and explored whether clinical
subphenotypes can be discerned within anti-CCP-negative RA.
Methods: The 318 patients with anti-CCP-negative RA (1987 ACR criteria), included in the Leiden Early Arthritis
Clinic between 1993 and 2006, were studied for baseline characteristics and radiologic progression data during a
mean follow-up of 5 years. Grouping was studied both at variable and patient levels. Principal components analysis
and partial least-squares regression were applied to study for clustering of variables. A cluster analysis was
performed to look for clustering of patients.
Results: The simultaneous presence of patient characteristics at disease presentation was observed for several
groups; however, the three largest groups of patients’ characteristics explained only 26.5% of the total variance.
Plotting the contribution of each patient to these three groups did not reveal clustering of patients. Comparable
observations were made when data on progression of joint destruction were studied in relation to baseline clinical
data. A cluster analysis, evaluating whether patients resemble each other, revealed no grouping of patients.
Altogether, no clinically distinguishable subphenotypes were observed.
Conclusions: The current data provide evidence that, for risk-factor studies, anti-CCP-negative RA patients can be
studied as one group.
Introduction
Rheumatoid arthritis (RA) has been considered a rela-
tively homogeneous clinical syndrome for more than 50
years. However, our current view of RA as a single dis-
ease may become untenable, and the disease may be
subdivided into a range of disorders based on improved
knowledge of its driving immunologic markers [1-3].
During the last decade, a number of studies suggested
that RA can be divided into two syndromes: anti-citrulli-
nated peptide antibody (CCP)-positive and anti-CCP-
negative RA. This subdivision was based on differences
in genetic risk factors, histopathologic differences, and
differences in outcome of anti-CCP-positive and anti-
CCP-negative RA [4].
S e v e r a ls u c c e s s f u lg e n o m e - w i d es t u d i e sf o rg e n e t i c
risk factors for anti-CCP-positive RA have been per-
formed. Studies on genetic risk factors for anti-CCP-
negative RA are thus far lacking. One of the reasons for
this is the fear of phenotypic misclassification, as anti-
CCP-negative RA is often considered to be a heteroge-
neous disease [1,5]. For future risk-factor, translational,
and outcome studies on the subgroup of anti-CCP-nega-
tive RA patients, it is essential to provide epidemiologic
and clinical evidence on whether anti-CCP-negative RA
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aimed to determine whether the group of anti-CCP-
negative RA patients can be separated into clinically dis-
tinguishable subphenotypes.
Materials and methods
Patients
The 704 patients who were included between 1993 and
2006 in the Leiden Early Arthritis Clinic and who were
diagnosed with RA according to the 1987 ACR criteria
were selected; 318 patients had anti-CCP-negative RA
and were therefore selected for further analysis. The Lei-
den Early Arthritis Clinic previously has been described
extensively [6]. In short, it is a population-based incep-
tion cohort of patients presenting with arthritis to the
Department of Rheumatology of the Leiden University
Medical Center. This is the only referral center in a
health care region of approximately 400,000 inhabitants.
Written informed consent was obtained from all
patients, and the cohort was approved by the local med-
ical ethical committee (Ethics Committee of the Leiden
University Medical Center). At first visit, the rheumatol-
ogist completed a questionnaire regarding the present-
ing symptoms, as reported by the patient: type,
localization and distribution of initial joint symptoms,
duration and course of the initial symptoms, and the
presence of inflammatory back pain and skin abnormal-
ities. The patient’s smoking history and family history
were assessed. Patients rated morning stiffness in min-
utes (mean, 103; SD, 112). The Health Assessment
Questionnaire (HAQ) was used to provide an index of
disability. A 44-joint count for swollen joints (SJC) was
performed. Anti-CCP2 antibodies were measured in sera
collected at baseline with enzyme-linked immunosor-
bent assay (ELISA) (Immunoscan RA Mark 2; Eurodiag-
nostica, Arnhem, The Netherlands). Samples with a
value less than 25 units/ml were considered negative,
according to the manufacturer’s instructions. IgM-Rheu-
matoid Factor (RF) was determined with ELISA. RF
titers ranged from 0 to 200 IU/ml. For the analyses, RF
levels titers were divided into three groups: RF normal,
RF moderately increased (1 to 3 times the reference
value), and RF highly increased (> 3 times reference
value) [7]. Anti-modified citrullinated vimentin (MCV)
antibodies were also measured with ELISA (Orgentec
Diagnostika, Mainz, Germany); here, the cutoff level was
20 arbitrary units, according to the manufacturer’s
instruction. All the mentioned baseline variables were
studied here, as they may, on their own or in combina-
tion with other characteristics, point to different disease
subsets. Annual radiographs of the hands and feet were
taken during a mean follow-up period of 5 years (mini-
mum, 0; maximum, 14 years) and scored according to
the Sharp-van der Heijde method (SHS) by an
experienced reader. The intraclass observer correlation
coefficient for the radiographic progression rate was
0.97. The radiographic SHS progression per year was
calculated for each patient by using a linear regression
analysis with the following formula: Y = a + bx. All
available radiographs per patient were used to estimate
ap a t i e n t ’s progression rate (the b in the equation). At a
group level, the median SHS values (± SD) at the subse-
quent time points were 5.0 (9.8) at baseline; 7.0 (13.3) at
1-year follow-up; 9.0 (15.6) at 2 years; 9.0 (17.2) at 3
years; and 10.5 (22.4) at 5 years of follow-up.
Statistical analysis
To investigate whether clinical subphenotypes can be
discerned, two types of analyses were done. First, we
studied whether groups of patient characteristics fre-
quently occur together; such clustering at the variable
level was studied by using the variable reduction techni-
ques Principal Components Analysis (PCA) and Partial
Least Squares regression (PLS). Second, we studied
whether subgroups of patients can be discerned; such
grouping at the patient level was studied by using a
cluster analysis.
PCA
Some overlap between clinical variables is extremely
common (for example, a high swollen-joint count will
often be accompanied by a high number of tender
joints). PCA makes use of such overlap and combines
variables that frequently occur together into compo-
nents. In this way, the number of variables explaining
data can be reduced, which makes datasets easier to
interpret. The components resulting from the PCA are
b a s e do nt h eo b s e r v e dv a r i a n c ea n dn o to np r e d e f i n e d
hypotheses, making this technique suitable for exploring
unknown relations between variables. For each compo-
nent, the loading of each variable to the component is
provided. Loadings > 0.4 are generally considered rele-
vant. For each component, an observed variance is pre-
sented, indicating the percentage of the total variance in
clinical variables that is explained by this component.
Here, a PCA was performed, and the contribution of
each patient to the most important components was
plotted to look for clustering of patients. The PCA was
performed by using the following baseline variables: age
at inclusion, gender, symptom duration, acuteness of the
onset of symptoms (subacut e ,w i t h i n1w e e k ,o ri n s i -
dious, over more than 1 week),m o r n i n gs t i f f n e s s ,f a t i -
gue, fever, smoking, family history of RA, three variables
on the distributions of involved joints (upper extremi-
ties, lower extremities, or both; symmetric or asym-
metric; large joints, small joints, or both), C-reactive
protein, RF, the presence of baseline erosions, the num-
ber of swollen joints, anti-MCV positivity, inflammatory
back pain, and skin abnormalities.
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A limitation of PCA is that it cannot take outcome mea-
sures into account. Because patient response obtained
during the disease course is at least of equal importance
to baseline characteristics for the aim of the present
study, we also performed a Partial Least Squares regres-
sion. PLS does an analysis that is comparable to PCA,
but that has the advantage that it makes use also of out-
come measures [8]. Here, a PLS regression was applied
to the same variables as included in the PCA as inde-
pendent variables, but with the addition of the radiolo-
gic damage over time as a dependent variable. This
analysis allowed us to assess whether variance between
patients can be characterized by distinguishable sub-
groups. Also here, identified factors were plotted to look
for clustering, which may represent clinical subpheno-
types. The PCA and PLS analyses were done by using
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). To
perform PLS, the relevant SPSS extension packages were
downloaded from the links provided by the official SPSS
website.
Cluster analysis
Subsequently, a cluster analysis was performed, which,
in contrast to PCA and PLS, evaluates not grouping of
patient characteristics, but grouping of patients. In other
words, given all characteristics that were available of the
patients, this evaluated which patients resemble each
other. Accordingly, not the variables denoting them, but
the patients themselves are subject to combination into
clusters. Hierarchic clustering was performed by using
Gene Cluster, as described by Eisen et al.[ 9 ]
Results
PCA
The baseline characteristics of the anti-CCP-negative RA
patients are depicted in Table 1. Entering baseline vari-
ables into a PCA resulted in nine components. The first
component explained 10.0% of the variance, the second
component, 8.6%, and the third component, 8.0%. The
relative importance of the variables contributing to the
different components is depicted in Table 1. For exam-
ple, in the first component, the variables age, gender,
and the presence of baseline erosions were grouped. In
the second component, the involvement of small joints
versus the involvement of large joints or both SJC and
CRP were grouped. The component scores for indivi-
dual patients of factors 1 through 3 were plotted against
each other, and no evident clustering was observed
Table 1 Baseline characteristics of the study population and the factors found in PCA
Component
Variable Baseline frequency 1 2 3 4 5 6789
Age at inclusion (years, mean ± SD) 59.2 (16.2) 0.761
Female gender (n, %) 219 (68.9) 0.448 0.394
Subacute onset of symptoms (versus insidious) 188 (59.1) 0.592 -0.306 0.316
Morning stiffness (min; mean ± SD) 103.18 (112.0) -0.496 0.484
Fatigue (VAS; mean ± SD) 45.1 (29.9) -0.389 0.522
Symptom duration (days; mean ± SD) 172.1 (180.2) 0.394 -0.349 0.455
Family history of RA (n, %) 62 (19.5) -0.326 0.594 0.380
Past or present smoking (n, %) 128 (40.3) 0.652 0.375
Fever (n, %) 22 (6.9) -0.319 -0.426
Involvement of small/large joints (n,% )
a 0.604
Symmetry of involved joints (n, %) 216 (67.9) -0.379 0.308 0.331 0.370
Involvement of upper/lower extremities
b 0.602 -0.348
Inflammatory back pain (n, %) 16 (5.0) 0.466 0.531 0,321
Skin abnormalities (N, %)
c 56 (18.1) 0.374
Swollen joint count (mean ± SD)
d 11.3 (8.5) 0.445 0.365
CRP (mg/L; mean ± SD) 30.10 (34.4) 0.315 0.434 0.512
RF (IU/ml) (mean ± SD)
e 7.12 (19.5) 0.305 -0.345 0.315 -0.602
MCV positivity (n, %) 59 (18.6) 0.470 0.376 -0.321
Erosive disease at baseline (n, %) 202 (63.5) 0.642 0.332
Explained variance per component (%) 10.0 8.6 8.0 7.4 6.8 6.5 5.6 5.5 5.4
Involvement of upper extremities: shoulder, elbow, wrist, or hand joints; involvement of lower extremities: joints of hip, knee, ankle, feet or toe joints.
aInvolvement of small/large joints: in 163 patients (51.3%), only small joints of hands and feet were involved. In 53 patients (16.7%) only large joints were
involved. In 93 patients (29.2%), both small and large joints were involved.
aInvolvement of upper/lower extremities: in 156 patients (49.1%) only joints in the
upper extremities were involved. In 28 patients (8.8%), only joints in the lower extremities were involved. In 96 (30.2%) patients, joints in both lower and upper
extremities were involved.
cSkin abnormalities: absence or presence of dermatological abnormalities such as psoriatic lesions, ulcers, rheumatoid nodules and so
on.
dSwollen Joint Count: 44-Swollen Joint Count.
eAnalyses were performed on RF in groups (less than reference value, 1 to 3 times reference value, or more than
3 times reference value). CRP, C-reactive protein; MCV, mutated citrullinated vimentin; RF, rheumatoid factor; VAS, visual analogue scale.
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most variance, these components were plotted. In these
plots, each dot indicates one single patient. For example
in Figure 1a, a dot indicates how much the variance in
an individual patient is described by factor 1 (age, gen-
der, and the presence of baseline erosions) in relation to
factor 2 (involvement of small joints versus the involve-
ment of large joints or both SJC and CRP).
PLS
Apart from baseline characteristics, outcome data may
be informative to identify differences between patient
populations, so we next performed a data-reduction
method that allows assessing radiologic-outcome data in
addition to baseline data. To identify subsets of patients,
PLS regression was used. With PLS, two latent factors
were found that together accounted for 30.1% of the
observed variation. The major important variables in the
first latent factor were gender, symmetry of involved
joints, rheumatoid factor positivity, anti-MCV positivity,
age at inclusion, symptom duration at inclusion, and the
presence of baseline erosions. The major variables in the
second factor were the same; this suggests that little dif-
f e r e n c ee x i s t s .T h ei n d i v i d u a lp a t i e n ts c o r e so nt h e s e
factors were plotted against each other. Also here, no
clustering was observed (Figure 1d).
Because of the absence of clustering, we sought a
positive control, to verify that the method and data used
d oa l l o wf i n d i n gc l u s t e r s .T ot h i se n d ,t h eP L Sw i t h
baseline and radiologic progression data was repeated
on the total group of 704 RA patients instead of on the
subgroup of anti-CCP-negative patients. Anti-CCP sta-
tus was not included in this analysis, so that the analysis
was not influenced by this variable. Again, two factors
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Figure 1 Plots of the most important component loadings from PCA and PLS on 318 anti-CCP-negative RA patients. In these plots,
each dot indicates one single patient. Component scores indicate how strongly each component is represented in each patient. For example, in
(a), a dot indicates how much the variance in an individual patient is being described by factor 1 on the x-axis (age, gender, and the presence
of baseline erosions) in relation to factor 2 on the y-axis (involvement of small joints versus the involvement of large joints or both SJC and
CRP). If a concurrence of components was found, clustering of patients would be visible. In the PCA, clinical variables at disease onset were
explored. The same applies for the factors in PLS regression. In the PLS regression, the clinical variables at disease onset were explored together
with radiologic data on progression of joint destruction during a mean of 5 years of disease. CRP, C-reactive protein; PCA, principal components
analysis; PLS, partial least squares regression; RA, rheumatoid arthritis; SJC, swollen joint count.
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variance. The main variables of these components were
gender, rheumatoid factor, age at inclusion, and CRP.
Clustering the first two factors revealed two clusters;
one for anti-CCP-positive patients and one for anti-
CCP-negative patients (see Figure 2).
Cluster analysis
Finally, we explored whether anti-CCP-negative patients
can be grouped into subgroups of patients with similar
characteristics. To this end, a heat map was made in
which the patients with the most similarity clustered
together. Cluster analysis showed no clustering of
patients in the heat map, and this finding is supported
by the dendrogram (Figure 3). Therefore, also with these
analyses, no distinguishable groups of patients with
similar characteristics were recognized.
Sensitivity analysis
Patients negative for anti-CCP antibodies can harbor
other autoantibodies. Here 24.2% of the anti-CCP-nega-
tive patients were positive for RF, and 18.6% were posi-
tive for anti-MCV. It can be argued that it is more
appropriate to perform the analyses on patients negative
for anti-CCP, RF, and anti-MCV. Therefore, all analyses
were repeated in this subgroup (n = 171). Similar obser-
vations were made (data not shown).
Discussion
This study determined whether anti-CCP-negative
patients fulfilling the 1987 ACR criteria for RA can be
subdivided into clinical subphenotypes and explored
extensive phenotypic characteristics at baseline, as well
as data on progression in joint destruction during the
disease course. In addition, several methods were
applied, intending to find subgroups of either variables
or patients. With any method used, no clearly distin-
guishable clusters were observed, although the methods
used did distinguish CCP-positive and CCP-negative
patients as identifiable subphenotypes. Therefore, these
data do not support the hypothesis that anti-CCP-nega-
tive RA is composed of different subsets, but rather pro-
vide evidence that anti-CCP-negative RA can be
regarded as one disease, and therefore, risk-factor stu-
dies in anti-CCP-negative RA are feasible.
The data evaluated concerned a wide variety of clinical
characteristics, such as the acuteness of the onset of
symptoms, the distribution of involved joints, the sever-
ity of fatigue, fever, skin abnormalities, inflammatory
back pain, acute-phase reactants, and radiologic baseline
and progression data. The variables assessed are, in our
view, variables that might in combination form patterns
characteristic of different disease subsets. However,
despite the evaluation of a large range of characteristics
at disease presentation and the evaluation of long-term
radiologic follow-up data, no clear subphenotypes were
discerned. We cannot exclude that when other variables
are assessed, conclusions might be different.
To test whether the currently used data and methods
are able to find clinical subsets, we also studied the total
RA population, including 704 patients, of whom 318
were anti-CCP-negative patients. We observed that PLS
regression is able to discriminate between anti-CCP-
positive and anti-CCP-negative disease. This is in line
with published data that anti-CCP-positive RA has more
progressive joint destruction during the disease course
than does anti-CCP-negative RA [10]
The present study did not aim to find statistically sig-
nificant associations of baseline variables with the out-
come. The present study also does not give any
indication on whether the pathogenesis of anti-CCP-
negative RA is heterogeneous or homogeneous between
patients. We explored whether clinical data provide evi-
dence that different groups of patients compose the
group of anti-CCP-negative RA patients. If subclinical
phenotypes had been identified, this is relevant for
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Figure 2 Plots of the two major component loadings from PLS on the whole Leiden Early Arthritis Clinic (n = 704). Each dot indicates
one patient. Component scores indicate how strongly each component is represented in each patient. Patients positive for anti-CCP antibodies
are blue, whereas negative patients are red. CCP, citrullinated peptide antibody; PLS, partial least squares regression.
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gested that, to prevent phenotypic misclassification,
studies should be done on anti-CCP-negative subpheno-
types. The present observation of a lack of phenotypic
heterogeneity within anti-CCP-negative RA suggests that
future studies on pathogenic mechanisms underlying
anti-CCP-negative RA can be done on the total popula-
tion of anti-CCP-negative patients.
Conclusions
Based on the present data, we suggest that risk factors
studied on the anti-CCP-negative RA patients can be
performed on the total group of 1987 ACR criteria-posi-
tive, anti-CCP-negative RA patients.
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Figure 3 Heat map of the cluster analysis of 318 anti-CCP-negative RA patients. Heat map representing the presence or absence of
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a continuous scale, the following cut-offs were made: Morning Stiffness, ≤60 minutes; Fatigue, fatigue rated more than mean (45.1) on Visual
Analogue Scale; symptom duration more than or ≤12 weeks age at inclusion, age greater than mean age (59.2 years); swollen joint count, more
than four swollen joints; CRP, CRP greater than reference value (10 mg/L). The dendrograms depict the relative strength of correlations between
the variables and the patients, respectively. CCP, citrullinated peptide antibody; CRP, C-reactive protein; RA, rheumatoid arthritis; SJC, swollen joint
count; VAS, visual analogue scale.
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